
## Emilio J Sanz Alvarez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/855697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries. Revista De PsiquiatrÃa Y Salud Mental, 2022, 15, 238-250.	1.8	31
2	Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase. Expert Review of Clinical Pharmacology, 2022, 15, 65-78.	3.1	18
3	Ethical Dilemmas with Regard to Elderly Patients with Hip Fracture: The Problem of Nonagenarians and Centenarians. Journal of Clinical Medicine, 2022, 11, 1851.	2.4	4
4	The European Prescribing Exam: assessing whether European medical students can prescribe rationally and safely. European Journal of Clinical Pharmacology, 2022, 78, 1049-1051.	1.9	7
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
6	Clozapine and the risk of haematological malignancies. Lancet Psychiatry,the, 2022, 9, 537-538.	7.4	12
7	Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics. British Journal of Clinical Pharmacology, 2021, 87, 1001-1011.	2.4	12
8	EurOP2E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers. European Journal of Clinical Pharmacology, 2021, 77, 1209-1218.	1.9	6
9	European List of Essential Medicines for Medical Education: a protocol for a modified Delphi study. BMJ Open, 2021, 11, e045635.	1.9	5
10	Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other secondâ $\in$ generation antipsychotics. World Psychiatry, 2020, 19, 120-121.	10.4	60
11	Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions. Schizophrenia Bulletin, 2020, 46, 1-3.	4.3	75
12	The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. Psychological Medicine, 2020, , 1-2.	4.5	1
13	Knowledge, Attitudes and Expectations of Physicians with Respect to Palliative Care in Ecuador: A Qualitative Study. International Journal of Environmental Research and Public Health, 2020, 17, 3906.	2.6	9
14	Fentanyl treatment for end-of-life dyspnoea relief in advanced cancer patients. Supportive Care in Cancer, 2019, 27, 157-164.	2.2	10
15	Spanish list of potentially inappropriate drugs in the elderly (ES-PIA project). European Journal of Clinical Pharmacology, 2019, 75, 1161-1176.	1.9	11
16	Appropriate antibiotic prescribing among final-year medical students in Europe. International Journal of Antimicrobial Agents, 2019, 54, 375-379.	2.5	14
17	Acidosis con hiperlactacidemia por metformina: frecuencia de su diagnóstico en la práctica clÃnica habitual y relación con la insuficiencia renal. Revista Clinica Espanola, 2019, 219, 236-242.	0.6	3
18	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. Clinical Pharmacology and Therapeutics, 2018, 104, 317-325.	4.7	46

#	Article	IF	CITATIONS
19	Pharmacology and Therapeutics Education in the European Union Needs Harmonization and Modernization: A Crossâ€sectional Survey Among 185 Medical Schools in 27 Countries. Clinical Pharmacology and Therapeutics, 2017, 102, 815-822.	4.7	58
20	Essential competencies in prescribing: A first european crossâ€sectional study among 895 finalâ€year medical students. Clinical Pharmacology and Therapeutics, 2017, 101, 281-289.	4.7	65
21	Bioética del dÃa a dÃa: más allá de los expertos. Revista Clinica Espanola, 2016, 216, 255-256.	0.6	2
22	Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clÃnica. Revista Iberoamericana De Psicologia Y Salud, 2016, 7, 25-30.	0.9	4
23	Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase®. Drug Safety, 2016, 39, 69-78.	3.2	70
24	A case-non case evaluation of the psychiatric disorder and statins association in FEDRA Database. Clinical Therapeutics, 2015, 37, e150.	2.5	0
25	The relationship of psychological reactance, health locus of control and sense of self-efficacy with adherence to treatment in psychiatric outpatients with depression. BMC Psychiatry, 2014, 14, 324.	2.6	34
26	Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. European Journal of Clinical Pharmacology, 2014, 70, 89-98.	1.9	63
27	Psychiatric outpatients' selfâ€reported adherence versus psychiatrists' impressions on adherence in affective disorders. Human Psychopharmacology, 2013, 28, 142-150.	1.5	14
28	Mental health professionals' attitudes to partnership in medicine taking: a validation study of the Leeds Attitude to Concordance Scale II. Pharmacoepidemiology and Drug Safety, 2012, 21, 123-129.	1.9	16
29	¿Están relacionadas la obesidad y otras comorbilidades fÃsicas con la enfermedad mental?. Revista De PsiquiatrÃa Y Salud Mental, 2011, 4, 119-125.	1.8	4
30	Are obesity and other physical comorbidities related to mental illness?. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2011, 4, 119-125.	0.3	2
31	Antidepressant Use in Early Pregnancy. Current Women's Health Reviews, 2011, 7, 10-17.	0.2	0
32	Adaptation and validation study of the Beliefs about Medicines Questionnaire in psychiatric outpatients in a community mental health setting. Human Psychopharmacology, 2011, 26, 140-146.	1.5	34
33	Users Perception of Risk and Benefits of Mood Modifying Drugs. Current Clinical Pharmacology, 2011, 6, 108-114.	0.6	1
34	Lithium Use During Early, Late Pregnancy, and Breastfeeding. Current Women's Health Reviews, 2011, 7, 46-49.	0.2	0
35	Psychomotor performance and fitness to drive: The influence of psychiatric disease and its pharmacological treatment. Psychiatry Research, 2010, 176, 236-241.	3.3	25
36	Further Psychometric Validation of the Sexual Life Quality Questionnaire for Men with Erectile Dysfunction and Their Partners on a Modified Spanish Language Version. Journal of Sexual Medicine, 2009, 6, 2698-2706.	0.6	17

EMILIO J SANZ ALVAREZ

#	Article	IF	CITATIONS
37	Social, cultural and ethical aspects of drug use—changes over 40Âyears: a personal look back. European Journal of Clinical Pharmacology, 2008, 64, 107-114.	1.9	5
38	Should medical students learn to develop a personal formulary?. European Journal of Clinical Pharmacology, 2008, 64, 641-646.	1.9	34
39	Fitness to Drive of Psychiatric Patients. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 384-390.	0.6	21
40	La evaluaci $ ilde{A}^3$ n cualitativa en la formaci $ ilde{A}^3$ n m $ ilde{A}$ ©dica continuada. Educacion Medica, 2008, 11, .	0.3	0
41	Duloxetine-Induced Excessive Disturbing and Disabling Yawning. Journal of Clinical Psychopharmacology, 2007, 27, 106-107.	1.4	14
42	Validación psicométrica del cuestionario SLQQ. Resultados preliminares. Revista Internacional De AndrologÃa, 2007, 5, 5-10.	0.3	7
43	Are psychotropics drugs used in pregnancy?. Pharmacoepidemiology and Drug Safety, 2007, 16, 1018-1023.	1.9	4
44	Attitudes toward psychiatric drug treatment: the experience of being treated. European Journal of Clinical Pharmacology, 2007, 63, 1063-1067.	1.9	24
45	Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy. Current Drug Safety, 2006, 1, 17-24.	0.6	20
46	Polypsychopharmacy. Journal of Clinical Psychopharmacology, 2005, 25, 510-512.	1.4	10
47	Pharmacoepidemiology and the ?Impact Factor?. European Journal of Clinical Pharmacology, 2005, 60, 765-772.	1.9	5
48	Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, The, 2005, 365, 482-487.	13.7	363
49	Prescribers' indications for drugs in childhood: A survey of five European countries (Spain, France,) Tj ETQq1 1 0.7 1784-1790.	784314 rg 1.5	BT /Overlock 5
50	Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, The, 2005, 365, 482-487.	13.7	80
51	Prescribers' indications for drugs in childhood: A survey of five European countries (Spain, France,) Tj ETQq1 1 0. 1784-1790.	784314 rg 1.5	BT /Overlock 11
52	Patient Adherence to Medical Treatment Regimens: Bridging the Gap Between Behavioral Science and Biomedicine. BMJ: British Medical Journal, 2005, 330, 1155.1.	2.3	3
53	Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry, 2004, 4, 18.	2.6	51
54	Pharmacological treatment of acute otitis media in children. A comparison among seven locations: Tenerife, Barcelona and Valencia (Spain), Toulouse (France), Smolensk (Russia), Bratislava (Slovakia) and Sofia (Bulgaria). European Journal of Clinical Pharmacology, 2004, 60, 37-43.	1.9	15

## EMILIO J SANZ ALVAREZ

#	Article	IF	CITATIONS
55	Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). European Journal of Clinical Pharmacology, 2004, 60, 127-134.	1.9	26
56	Do therapeutic indications of antidepressants change from one year to another?. Pharmacoepidemiology and Drug Safety, 2004, 13, 309-314.	1.9	26
57	The significance of drug utilization for Public Health. , 2004, , 99-117.		0
58	Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology, 2003, 167, 297-303.	3.1	80
59	Concordance and children's use of medicines. BMJ: British Medical Journal, 2003, 327, 858-860.	2.3	49
60	Comités éticos de investigación clÃnica y «dictamen único» de los ensayos clÃnicos multicéntricos. Medicina ClÃnica, 2003, 120, 180-188.	0.6	3
61	Variations in antidepressant prescribing practice: clinical need or market influences?. Pharmacoepidemiology and Drug Safety, 2002, 11, 515-522.	1.9	31
62	Perception of teratogenic risk of common medicines. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 95, 127-131.	1.1	88
63	Are antibiotics overprescribed in primary care?. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 1223-1225.	1.5	1
64	Pharmacogenetic Profile of Xenobiotic Enzyme Metabolism in Survivors of the Spanish Toxic Oil Syndrome. Environmental Health Perspectives, 2001, 109, 369.	6.0	3
65	Are antibiotics overprescribed in primary care?. Acta Paediatrica, International Journal of Paediatrics, 2001, 90, 1223-1225.	1.5	1
66	The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction, 2000, 95, 245-250.	3.3	122
67	Benzodiazepine prescription is different in the public and private sectors. , 1999, 8, 351-353.		5
68	Reacciones adversas y problemas relacionados con medicamentos en un servicio de urgencia. Revista Espanola De Salud Publica, 1999, 73, .	0.3	6
69	Drug prescribing for children in general practice. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 489-490.	1.5	5
70	Separation and quantitation of debrisoquine and 4-hydroxydebrisoquine in human urine by capillary electrophoresis and high-performance liquid chromatography. Journal of Chromatography A, 1997, 778, 389-396.	3.7	12
71	The network of pediatric pharmacology training programs. Clinical Pharmacology and Therapeutics, 1993, 54, 1-6.	4.7	7
72	Drug use in non-hospitalized children. Pharmaceutisch Weekblad Scientific Edition, 1992, 14, 1-8.	0.9	7

EMILIO J SANZ ALVAREZ

#	Article	IF	CITATIONS
73	Steadyâ€ <b>s</b> tate concentrations and dosage of digoxin in relation to kidney function in hospitalized patients over 70 years of age. Journal of Internal Medicine, 1991, 229, 247-251.	6.0	4
74	d-Propoxyphene is a Potent Inhibitor of Debrisoquine, but Not S-Mephenytoin 4-Hydroxylation In Vivo. Therapeutic Drug Monitoring, 1990, 12, 297-299.	2.0	15
75	Diuretic effect and diuretic efficiency after intravenous dosage of frusemide [see comments]. British Journal of Clinical Pharmacology, 1990, 29, 215-219.	2.4	30
76	Poor hydroxylator phenotypes of debrisoquine and Sâ€mephenytoin are not overâ€represented in a group of patients with Parkinson's disease [letter]. British Journal of Clinical Pharmacology, 1990, 30, 301-302.	2.4	21
77	Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 1989, 45, 348-355.	4.7	260
78	S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clinical Pharmacology and Therapeutics, 1989, 45, 495-499.	4.7	122
79	Diazepam Treatment Does Not Influence the Debrisoquine or Mephenytoin Hydroxylation Phenotyping Tests. Therapeutic Drug Monitoring, 1989, 11, 721-723.	2.0	6
80	Depression associated with diltiazem BMJ: British Medical Journal, 1989, 299, 796-796.	2.3	27
81	Paediatric drug prescribing. A comparison of Tenerife (Canary Islands, Spain) and Sweden. European Journal of Clinical Pharmacology, 1989, 37, 65-68.	1.9	35
82	Drug utilization by children in Tenerife Island. European Journal of Clinical Pharmacology, 1988, 34, 495-499.	1.9	30
83	Inhibitory effect of naloxone on the ethanol-induced antinociception in mice. Pharmacological Research Communications, 1981, 13, 673-678.	0.2	35